Patient recruitment and retention is a challenge in clinical research—especially in ultra-rare orphan diseases with a limited number of patients and several competing trials.

Download this case study to see how Rezolute, a small biotech company, became a sponsor of choice for patients and sites with the Medidata Platform by:

• Reducing study startup time
• Improving study compliance
• Delivering a superior patient and site experience
• Streamlining communication between all trial stakeholders
• Allowing Rezolute to focus on core tasks rather than managing multiple vendors

About Rezolute

Rezolute is a small biotech company advancing targeted therapies for rare, metabolic, and life-threatening diseases. Its lead clinical asset, RZ358, was found to be effective in a Phase 2b trial as a potential treatment for congenital hyperinsulinism (CHI), an ultra-rare pediatric endocrine disorder.